Version 1
: Received: 5 September 2019 / Approved: 6 September 2019 / Online: 6 September 2019 (15:47:26 CEST)
Version 2
: Received: 8 September 2019 / Approved: 9 September 2019 / Online: 9 September 2019 (08:46:04 CEST)
How to cite:
Sayed, S.B.; Nain, Z.; Abdullah, F.; khan, M.S.A.; Haque, Z.; Rahman, S.R.; Tasmin, R.; Adhikari, U.K. Immunoinformatics-guided Designing of Peptide Vaccine against Lassa Virus with Dynamic and Immune Simulation Studies. Preprints2019, 2019090076 (doi: 10.20944/preprints201909.0076.v1).
Sayed, S.B.; Nain, Z.; Abdullah, F.; khan, M.S.A.; Haque, Z.; Rahman, S.R.; Tasmin, R.; Adhikari, U.K. Immunoinformatics-guided Designing of Peptide Vaccine against Lassa Virus with Dynamic and Immune Simulation Studies. Preprints 2019, 2019090076 (doi: 10.20944/preprints201909.0076.v1).
Cite as:
Sayed, S.B.; Nain, Z.; Abdullah, F.; khan, M.S.A.; Haque, Z.; Rahman, S.R.; Tasmin, R.; Adhikari, U.K. Immunoinformatics-guided Designing of Peptide Vaccine against Lassa Virus with Dynamic and Immune Simulation Studies. Preprints2019, 2019090076 (doi: 10.20944/preprints201909.0076.v1).
Sayed, S.B.; Nain, Z.; Abdullah, F.; khan, M.S.A.; Haque, Z.; Rahman, S.R.; Tasmin, R.; Adhikari, U.K. Immunoinformatics-guided Designing of Peptide Vaccine against Lassa Virus with Dynamic and Immune Simulation Studies. Preprints 2019, 2019090076 (doi: 10.20944/preprints201909.0076.v1).
Abstract
Lassa virus (LASV) is responsible for a type of acute viral haemorrhagic fever referred to as Lassa fever. Lack of adequate treatment and preventive measures against LASV resulted in a high mortality rate in its endemic regions. In this study, a multi-epitope vaccine was designed using immunoinformatics as a prophylactic agent against the virus. Following a rigorous assessment, the vaccine was built using T-cell (NCTL=8 and NHTL=6) and B-cell (NLBL=4) epitopes from each LASV-derived protein with suitable linkers and adjuvant. The physicochemistry, immunogenic potency and safeness of the designed vaccine (~68 kDa) were assessed. In addition, chosen CTL and HTL epitopes of our vaccine showed 97.37% worldwide population coverage. Besides, disulphide engineering also improved the stability of the chimeric vaccine. Molecular docking of our vaccine protein with toll-like receptor (TLR2) showed binding efficiency followed by dynamic simulation for stable interaction. Furthermore, higher levels of cell-mediated immunity and rapid antigen clearance were suggested by immune simulation and repeated-exposure simulation, respectively. Finally, the optimized codons were used in in silico cloning to ensure higher expression within E. coli K12 bacterium. With further assessment both in vitro and in vivo, we believe that our proposed peptide-vaccine would be potential immunogen against Lassa fever.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sifat Bin Sayed
,